This toolkit contains messages and graphics highlighting coverage and access data from VIEW-hub that can be shared on social media platforms.

The VIEW-hub Report captures changes in introduction status and use for the vaccines monitored on VIEW-hub made between September 1–December 31, 2024.

The VIEW-hub report displays data and figures on the introduction, use, and coverage status of typhoid conjugate, human papillomavirus, pneumococcal, rotavirus, Hib, and inactivated polio vaccines both globally and in the 54 Gavi countries.

This checklist, intended for researchers, aims to improve comparability, consistency and reliability across SARS-CoV-2 neutralization studies thereby increasing utility for vaccine decision-making.

The VIEW-hub report displays data and figures on the introduction, use, and coverage status of typhoid conjugate, human papillomavirus, pneumococcal, rotavirus, Hib, and inactivated polio vaccines both globally and in the 54 Gavi countries.

This document outlines the methods used in the COVID-19 vaccines effectiveness and impact studies review. 

The Vaccine Economics Research for Sustainability and Equity (VERSE) project evaluated the status of vaccine coverage and equity status in the Democratic Republic of the Congo in 2013. Note: This resource is in French.

The VIEW-hub report displays data and figures on the introduction, use, and coverage status of typhoid conjugate, human papillomavirus, pneumococcal, rotavirus, Hib, and inactivated polio vaccines both globally and in the 54 Gavi countries.

The VIEW-hub report displays data and figures on the introduction, use, and coverage status of typhoid conjugate, human papillomavirus, pneumococcal, rotavirus, Hib, and inactivated polio vaccines both globally and in the 54 Gavi countries.

In partnership with the Asian Development Bank, IVAC developed factsheets and newsletters summarizing key measures for COVID-19 vaccines.